TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sought to determine the effect of anti-PD-1 and anti-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncoimmunology 2018-05, Vol.7 (8), p.e1466769-e1466769
Hauptverfasser:	Hung, Alice L., Maxwell, Russell, Theodros, Debebe, Belcaid, Zineb, Mathios, Dimitrios, Luksik, Andrew S., Kim, Eileen, Wu, Adela, Xia, Yuanxuan, Garzon-Muvdi, Tomas, Jackson, Christopher, Ye, Xiaobu, Tyler, Betty, Selby, Mark, Korman, Alan, Barnhart, Bryan, Park, Su-Myeong, Youn, Je-In, Chowdhury, Tamrin, Park, Chul-Kee, Brem, Henry, Pardoll, Drew M., Lim, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	CD155 checkpoint inhibitor dendritic cell GBM glioma immunotherapy Original Research PD-1 PVR TIGIT
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!